Imatinib, a selective inhibitor of the BCR–ABL tyrosine kinase, produces high response rates in patients with CML.[8] The bioavailability of the drug after oral administration is 98%. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.